amoxapine has been researched along with Akinetic-Rigid Variant of Huntington Disease in 2 studies
Amoxapine: The N-demethylated derivative of the antipsychotic agent LOXAPINE that works by blocking the reuptake of norepinephrine, serotonin, or both; it also blocks dopamine receptors. Amoxapine is used for the treatment of depression.
amoxapine : A dibenzooxazepine compound having a chloro substituent at the 2-position and a piperazin-1-yl group at the 11-position.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moldawsky, RJ | 1 |
| Lewis, CF | 1 |
| DeQuardo, JR | 1 |
| Tandon, R | 1 |
2 other studies available for amoxapine and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Effect of amoxapine on speech in a patient with Huntington's disease.
Topics: Adult; Amoxapine; Depressive Disorder; Dibenzoxazepines; Female; Humans; Huntington Disease; Speech; | 1984 |
ECT in genetically confirmed Huntington's disease.
Topics: Aged; Alleles; Amoxapine; Combined Modality Therapy; Depressive Disorder; Electroconvulsive Therapy; | 1996 |